Review





Similar Products

92
MedChemExpress psc833
Psc833, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psc833/product/MedChemExpress
Average 92 stars, based on 1 article reviews
psc833 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

93
Tocris p glycoprotein specific inhibitor psc833
P Glycoprotein Specific Inhibitor Psc833, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p glycoprotein specific inhibitor psc833/product/Tocris
Average 93 stars, based on 1 article reviews
p glycoprotein specific inhibitor psc833 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
Santa Cruz Biotechnology psc833
P-glycoprotein (P-gp) expression affects mitochondrial dye measurements in T cells. (a, b) MTG signals from splenic naïve (CD44 - CD62L + ) and memory (CD44 + CD62L + ) CD8 T cells stained with or without <t>PSC833</t> (1uM). (c) Protein expression level of P-glycoprotein based on Variance Stabilization Normalization (VSN) Normalized Intensities from proteomic analysis. (d, e) MTG and (f, g) TMRE signals from thymic CD4 T (CD8a - CD1d-aGC-tetramer - CD4 + TCRβ hi ) and iNKT (CD8a - CD1d-aGC-tetramer + TCRb int ) cells stained with or without PSC833 as in (a) . (h, i) MTG and (j, k) TMRE signals from PBMC CD4 T (CD8a - CD1d-aGC-tetramer - CD4 + TCRb hi ) and iNKT (CD8a - CD1d-aGC-tetramer + TCRb int ) cells stained with or without PSC833 as in (a) . The data shown in (a, b, d-k) are one representative experiment out of three independent experiments. The data shown in c are from samples collected from two sorting experiments and proteomes analyzed together. ns, non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, paired Student’s t test.
Psc833, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psc833/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
psc833 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Burlington Industries psc833 (cat#sml0572)
P-glycoprotein (P-gp) expression affects mitochondrial dye measurements in T cells. (a, b) MTG signals from splenic naïve (CD44 - CD62L + ) and memory (CD44 + CD62L + ) CD8 T cells stained with or without <t>PSC833</t> (1uM). (c) Protein expression level of P-glycoprotein based on Variance Stabilization Normalization (VSN) Normalized Intensities from proteomic analysis. (d, e) MTG and (f, g) TMRE signals from thymic CD4 T (CD8a - CD1d-aGC-tetramer - CD4 + TCRβ hi ) and iNKT (CD8a - CD1d-aGC-tetramer + TCRb int ) cells stained with or without PSC833 as in (a) . (h, i) MTG and (j, k) TMRE signals from PBMC CD4 T (CD8a - CD1d-aGC-tetramer - CD4 + TCRb hi ) and iNKT (CD8a - CD1d-aGC-tetramer + TCRb int ) cells stained with or without PSC833 as in (a) . The data shown in (a, b, d-k) are one representative experiment out of three independent experiments. The data shown in c are from samples collected from two sorting experiments and proteomes analyzed together. ns, non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, paired Student’s t test.
Psc833 (Cat#Sml0572), supplied by Burlington Industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psc833 (cat#sml0572)/product/Burlington Industries
Average 90 stars, based on 1 article reviews
psc833 (cat#sml0572) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Millipore psc833
Scutellarein enhances cisplatin-induced inhibition of cell viability and release of cytokeratin 18 fragments by inhibiting the PI3K/AKT-MDR1 pathway in NPC/HK1 cells. (A) NPC/HK1 cells were treated without (Ctrl) or with 12.5 µM scutellarein, 4.15 µM cisplatin, or their combination for 48 h. Protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. (B) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM LY294002 for 48 h. Upper panel, protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. (C) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM <t>PSC833</t> for 48 h. Upper panel, protein expression of MDR1 was examined using an immunoblotting assay. Middle panel, cell viability was assessed using the MTT assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. Statistical significance was indicated as follows: * P<0.05 vs. Ctrl; and # P<0.05 vs. Cis alone; n=3. p-, phosphorylated; MDR1, multidrug resistance protein 1; Ctrl, control; Scu, scutellarein; Cis, cisplatin; LY, LY294002.
Psc833, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psc833/product/Millipore
Average 90 stars, based on 1 article reviews
psc833 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Tocris p-gp transporter inhibitor psc833
Scutellarein enhances cisplatin-induced inhibition of cell viability and release of cytokeratin 18 fragments by inhibiting the PI3K/AKT-MDR1 pathway in NPC/HK1 cells. (A) NPC/HK1 cells were treated without (Ctrl) or with 12.5 µM scutellarein, 4.15 µM cisplatin, or their combination for 48 h. Protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. (B) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM LY294002 for 48 h. Upper panel, protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. (C) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM <t>PSC833</t> for 48 h. Upper panel, protein expression of MDR1 was examined using an immunoblotting assay. Middle panel, cell viability was assessed using the MTT assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. Statistical significance was indicated as follows: * P<0.05 vs. Ctrl; and # P<0.05 vs. Cis alone; n=3. p-, phosphorylated; MDR1, multidrug resistance protein 1; Ctrl, control; Scu, scutellarein; Cis, cisplatin; LY, LY294002.
P Gp Transporter Inhibitor Psc833, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p-gp transporter inhibitor psc833/product/Tocris
Average 90 stars, based on 1 article reviews
p-gp transporter inhibitor psc833 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Angene International Limited psc833
Scutellarein enhances cisplatin-induced inhibition of cell viability and release of cytokeratin 18 fragments by inhibiting the PI3K/AKT-MDR1 pathway in NPC/HK1 cells. (A) NPC/HK1 cells were treated without (Ctrl) or with 12.5 µM scutellarein, 4.15 µM cisplatin, or their combination for 48 h. Protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. (B) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM LY294002 for 48 h. Upper panel, protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. (C) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM <t>PSC833</t> for 48 h. Upper panel, protein expression of MDR1 was examined using an immunoblotting assay. Middle panel, cell viability was assessed using the MTT assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. Statistical significance was indicated as follows: * P<0.05 vs. Ctrl; and # P<0.05 vs. Cis alone; n=3. p-, phosphorylated; MDR1, multidrug resistance protein 1; Ctrl, control; Scu, scutellarein; Cis, cisplatin; LY, LY294002.
Psc833, supplied by Angene International Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psc833/product/Angene International Limited
Average 90 stars, based on 1 article reviews
psc833 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Tocris p-glycoprotein-specific inhibitor psc833
Scutellarein enhances cisplatin-induced inhibition of cell viability and release of cytokeratin 18 fragments by inhibiting the PI3K/AKT-MDR1 pathway in NPC/HK1 cells. (A) NPC/HK1 cells were treated without (Ctrl) or with 12.5 µM scutellarein, 4.15 µM cisplatin, or their combination for 48 h. Protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. (B) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM LY294002 for 48 h. Upper panel, protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. (C) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM <t>PSC833</t> for 48 h. Upper panel, protein expression of MDR1 was examined using an immunoblotting assay. Middle panel, cell viability was assessed using the MTT assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. Statistical significance was indicated as follows: * P<0.05 vs. Ctrl; and # P<0.05 vs. Cis alone; n=3. p-, phosphorylated; MDR1, multidrug resistance protein 1; Ctrl, control; Scu, scutellarein; Cis, cisplatin; LY, LY294002.
P Glycoprotein Specific Inhibitor Psc833, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p-glycoprotein-specific inhibitor psc833/product/Tocris
Average 90 stars, based on 1 article reviews
p-glycoprotein-specific inhibitor psc833 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

94
Tocris psc833 valspodar
Changes in P-glycoprotein (P-gp) transport activity in brain capillaries ( N = 15–20 per data point) from six rats treated with erastin. ( A ) Representative confocal fluorescent and DIC images of brain capillaries after a 60-min incubation with 2.0 μM NBD-CSA; note the high luminal fluorescence in the control capillary and ( B ) decreased luminal fluorescence in capillaries exposed to 10.0 μM <t>PSC833</t> (Scale bars, 10 μm). Representative confocal images of the luminal fluorescence (LF) from ( C ) male and female brain capillaries associated with P-glycoprotein (P-gp) transport activity at increasing doses of erastin in brain capillaries of SD rats. Bar graphs of P-glycoprotein transport activity determined by LF in ( D ) male and ( E ) female capillaries. Graphs of LF measuring P-glycoprotein (P-gp) transport activity in male ( F ) and female ( G ) capillaries (capillary N = 15–20 per experimental data point) exposed to 0.001 μM erastin over time. Dotted red line denotes multiple comparison. Significance is as compared to control unless otherwise specified: * p < 0.05, ** p < 0.01, *** p < 0.001.
Psc833 Valspodar, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psc833 valspodar/product/Tocris
Average 94 stars, based on 1 article reviews
psc833 valspodar - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


P-glycoprotein (P-gp) expression affects mitochondrial dye measurements in T cells. (a, b) MTG signals from splenic naïve (CD44 - CD62L + ) and memory (CD44 + CD62L + ) CD8 T cells stained with or without PSC833 (1uM). (c) Protein expression level of P-glycoprotein based on Variance Stabilization Normalization (VSN) Normalized Intensities from proteomic analysis. (d, e) MTG and (f, g) TMRE signals from thymic CD4 T (CD8a - CD1d-aGC-tetramer - CD4 + TCRβ hi ) and iNKT (CD8a - CD1d-aGC-tetramer + TCRb int ) cells stained with or without PSC833 as in (a) . (h, i) MTG and (j, k) TMRE signals from PBMC CD4 T (CD8a - CD1d-aGC-tetramer - CD4 + TCRb hi ) and iNKT (CD8a - CD1d-aGC-tetramer + TCRb int ) cells stained with or without PSC833 as in (a) . The data shown in (a, b, d-k) are one representative experiment out of three independent experiments. The data shown in c are from samples collected from two sorting experiments and proteomes analyzed together. ns, non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, paired Student’s t test.

Journal: Frontiers in Immunology

Article Title: P-glycoprotein expression skews mitochondrial dye measurements in T cells

doi: 10.3389/fimmu.2025.1560104

Figure Lengend Snippet: P-glycoprotein (P-gp) expression affects mitochondrial dye measurements in T cells. (a, b) MTG signals from splenic naïve (CD44 - CD62L + ) and memory (CD44 + CD62L + ) CD8 T cells stained with or without PSC833 (1uM). (c) Protein expression level of P-glycoprotein based on Variance Stabilization Normalization (VSN) Normalized Intensities from proteomic analysis. (d, e) MTG and (f, g) TMRE signals from thymic CD4 T (CD8a - CD1d-aGC-tetramer - CD4 + TCRβ hi ) and iNKT (CD8a - CD1d-aGC-tetramer + TCRb int ) cells stained with or without PSC833 as in (a) . (h, i) MTG and (j, k) TMRE signals from PBMC CD4 T (CD8a - CD1d-aGC-tetramer - CD4 + TCRb hi ) and iNKT (CD8a - CD1d-aGC-tetramer + TCRb int ) cells stained with or without PSC833 as in (a) . The data shown in (a, b, d-k) are one representative experiment out of three independent experiments. The data shown in c are from samples collected from two sorting experiments and proteomes analyzed together. ns, non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, paired Student’s t test.

Article Snippet: PSC833 was from Santa Cruz Biotechnology.

Techniques: Expressing, Staining

Scutellarein enhances cisplatin-induced inhibition of cell viability and release of cytokeratin 18 fragments by inhibiting the PI3K/AKT-MDR1 pathway in NPC/HK1 cells. (A) NPC/HK1 cells were treated without (Ctrl) or with 12.5 µM scutellarein, 4.15 µM cisplatin, or their combination for 48 h. Protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. (B) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM LY294002 for 48 h. Upper panel, protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. (C) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM PSC833 for 48 h. Upper panel, protein expression of MDR1 was examined using an immunoblotting assay. Middle panel, cell viability was assessed using the MTT assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. Statistical significance was indicated as follows: * P<0.05 vs. Ctrl; and # P<0.05 vs. Cis alone; n=3. p-, phosphorylated; MDR1, multidrug resistance protein 1; Ctrl, control; Scu, scutellarein; Cis, cisplatin; LY, LY294002.

Journal: Biomedical Reports

Article Title: Scutellarein enhances cisplatin‑induced apoptotic effects by suppressing the PI3K/AKT‑MDR1 pathway in human NPC/HK1 nasopharyngeal carcinoma cells

doi: 10.3892/br.2025.1938

Figure Lengend Snippet: Scutellarein enhances cisplatin-induced inhibition of cell viability and release of cytokeratin 18 fragments by inhibiting the PI3K/AKT-MDR1 pathway in NPC/HK1 cells. (A) NPC/HK1 cells were treated without (Ctrl) or with 12.5 µM scutellarein, 4.15 µM cisplatin, or their combination for 48 h. Protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. (B) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM LY294002 for 48 h. Upper panel, protein expression of p-AKT, AKT, MDR1, and GAPDH was examined using an immunoblotting assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. (C) NPC/HK1 cells were treated without (Ctrl) or with 4.15 µM cisplatin, or 4.15 µM cisplatin plus 10 µM PSC833 for 48 h. Upper panel, protein expression of MDR1 was examined using an immunoblotting assay. Middle panel, cell viability was assessed using the MTT assay. Lower panel, cytokeratin 18 fragment levels in the cell culture supernatant were measured by ELISA. Statistical significance was indicated as follows: * P<0.05 vs. Ctrl; and # P<0.05 vs. Cis alone; n=3. p-, phosphorylated; MDR1, multidrug resistance protein 1; Ctrl, control; Scu, scutellarein; Cis, cisplatin; LY, LY294002.

Article Snippet: Scutellarein, cisplatin, dimethyl sulfoxide (DMSO), 3-methyladenine (3-MA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), PSC833, and LY294002 were obtained from MilliporeSigma.

Techniques: Inhibition, Expressing, Western Blot, Cell Culture, Enzyme-linked Immunosorbent Assay, MTT Assay, Control

Changes in P-glycoprotein (P-gp) transport activity in brain capillaries ( N = 15–20 per data point) from six rats treated with erastin. ( A ) Representative confocal fluorescent and DIC images of brain capillaries after a 60-min incubation with 2.0 μM NBD-CSA; note the high luminal fluorescence in the control capillary and ( B ) decreased luminal fluorescence in capillaries exposed to 10.0 μM PSC833 (Scale bars, 10 μm). Representative confocal images of the luminal fluorescence (LF) from ( C ) male and female brain capillaries associated with P-glycoprotein (P-gp) transport activity at increasing doses of erastin in brain capillaries of SD rats. Bar graphs of P-glycoprotein transport activity determined by LF in ( D ) male and ( E ) female capillaries. Graphs of LF measuring P-glycoprotein (P-gp) transport activity in male ( F ) and female ( G ) capillaries (capillary N = 15–20 per experimental data point) exposed to 0.001 μM erastin over time. Dotted red line denotes multiple comparison. Significance is as compared to control unless otherwise specified: * p < 0.05, ** p < 0.01, *** p < 0.001.

Journal: Cancers

Article Title: A Role for iNOS in Erastin Mediated Reduction of P-Glycoprotein Transport Activity

doi: 10.3390/cancers16091733

Figure Lengend Snippet: Changes in P-glycoprotein (P-gp) transport activity in brain capillaries ( N = 15–20 per data point) from six rats treated with erastin. ( A ) Representative confocal fluorescent and DIC images of brain capillaries after a 60-min incubation with 2.0 μM NBD-CSA; note the high luminal fluorescence in the control capillary and ( B ) decreased luminal fluorescence in capillaries exposed to 10.0 μM PSC833 (Scale bars, 10 μm). Representative confocal images of the luminal fluorescence (LF) from ( C ) male and female brain capillaries associated with P-glycoprotein (P-gp) transport activity at increasing doses of erastin in brain capillaries of SD rats. Bar graphs of P-glycoprotein transport activity determined by LF in ( D ) male and ( E ) female capillaries. Graphs of LF measuring P-glycoprotein (P-gp) transport activity in male ( F ) and female ( G ) capillaries (capillary N = 15–20 per experimental data point) exposed to 0.001 μM erastin over time. Dotted red line denotes multiple comparison. Significance is as compared to control unless otherwise specified: * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: PSC833 (valspodar), the P-glycoprotein-specific inhibitor, was purchased from Tocris Bioscience.

Techniques: Activity Assay, Incubation, Fluorescence, Control, Comparison